Identifying and Eliminating Laboratory Contamination by Topical Testosterone Therapeutics-Reference-Cited by-同舟云学术

Identifying and Eliminating Laboratory Contamination by Topical Testosterone Therapeutics

Published:2019-01-01 Issue:1 Volume:65 Page:67-73
ISSN:0009-9147
Container-title:Clinical Chemistry
language:en
Short-container-title:

Author:

Genzen Jonathan R¹²,La'ulu Sonia L³,Wyness Sara P³,Scholes Kelly L¹,Signorelli Heather N¹²,Greer Ryan W¹

Affiliation:

1. ARUP Laboratories, Salt Lake City, UT

2. Department of Pathology, University of Utah, Salt Lake City, UT

3. ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT

Abstract

Abstract Many prescription and over-the-counter drugs are available as topical formulations. Contamination of clinical laboratory workspaces by topical drugs may increase the risk of potential interference with diagnostic testing. An example of localized workspace contamination attributed to a topical hormonal drug (testosterone, T) is presented to highlight significant challenges in identifying and resolving this potential problem. Investigation included precision studies, instrument service and parts replacement, instrument replacement, airflow analysis, environmental dust sampling, and the development of customized methods for workspace monitoring and cleaning. Laboratory policies and procedures were also revised to minimize future risk.

Publisher

Oxford University Press (OUP)

Subject

Biochemistry (medical),Clinical Biochemistry

Link

http://academic.oup.com/clinchem/article-pdf/65/1/67/32638230/clinchem0067.pdf

Reference7 articles.

1. A Lucas. Health hazard evaluation report. HETA 81–314-1435. National Institute for Occupational Safety and Health (NIOSH). March1984. https://www.cdc.gov/niosh/hhe/reports/pdfs/81-314-1435.pdf (Accessed September 2018).

2. S Billets. A literature review of wipe sampling methods for chemical warfare agents and toxic industrial chemicals. US Environmental Protection Agency, Washington, DC, EPA/600/R-07/004, 2007. https://permanent.access.gpo.gov/lps84975/600r07004.pdf (Accessed September 2018).

3. Surface and dermal monitoring for toxic exposures;Ness,1994

4. Testosterone II package insert. 2011-11 V3;Roche Diagnostics

5. Skin contamination by oestradiol gel—a remarkable source of error in plasma oestradiol measurements during percutaneous hormone replacement therapy;Vihtamaki;Maturitas,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Falsely elevated serum testosterone measurements resulting from testosterone topical gel contamination of the venipuncture site: Case Series and retrospective review;Heliyon;2023-12

2. The Optimal Time-lag for Testosterone Challenge Research Based on Salivary Profiles Following Different Doses of Transdermal Testosterone Administrations;Journal of Molecular Neuroscience;2023-04-24

3. Pretreatment of Body Fluid Specimens Using Hyaluronidase and Ultracentrifugation;Laboratory Medicine;2021-02-09

4. Wiping the Slate Clean—Assessing Clinical Laboratory Contamination Risk;Clinical Chemistry;2020-08-23

5. Evaluation of the Risk of Laboratory Microbial Contamination during Routine Testing in Automated Clinical Chemistry and Microbiology Laboratories;Clinical Chemistry;2020-08-13